In 2020 Touchlight AAV launched its state-of-the-art facility located in San Sebastian, Spain. The facility is comprised of four suites and additional support labs, that are specifically designed for the manufacture of high quality dbDNA.
We view dbDNA as a disruptive technology in the DNA market creating a new industry standard for transfection-based AAV production. Our synthetic process leads to high yield at small scales, shortening manufacturing timelines, facilitating quicker production of AAV and increasing safety by eliminating residual bacterial sequences of plasmid DNA in the AAV product.
To become the new industry standard DNA for AAV-based gene therapies.
To be a company with a strong technological base, which creates innovation and is a strategic partner in the development of gene therapies.
We are an ethical company, results-oriented and focused on the value of people above any other consideration. Our primary aim is to contribute to healing those who are beyond the hope of traditional therapeutics.